MA31565B1 - Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs - Google Patents

Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs

Info

Publication number
MA31565B1
MA31565B1 MA32490A MA32490A MA31565B1 MA 31565 B1 MA31565 B1 MA 31565B1 MA 32490 A MA32490 A MA 32490A MA 32490 A MA32490 A MA 32490A MA 31565 B1 MA31565 B1 MA 31565B1
Authority
MA
Morocco
Prior art keywords
oestrogenes
estratrienes
selectively active
beta substitution
preparations
Prior art date
Application number
MA32490A
Other languages
English (en)
Inventor
Olaf Peters
Nico Braeuer
Ina Thieme
Katja Prelle
Hans-Peter Muhn
Karl-Heinrich Fritzemeier
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31565B1 publication Critical patent/MA31565B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS ESTRA-1,3,5(10)-TRIÈNES À SUBSTITUTION 8ß DE FORMULE GÉNÉRALE (I) ; LEUR UTILISATION EN TANT QUE PRINCIPES ACTIFS PHARMACEUTIQUES, QUI PRÉSENTENT, IN VITRO, VIS-À-VIS DE PRÉPARATIONS DE RÉCEPTEURS D'¿STROGÈNES DE LA PROSTATE DE RATS, UNE AFFINITÉ SUPÉRIEURE À CELLE RELATIVE AUX PRÉPARATIONS DE RÉCEPTEURS D'¿STROGÈNES DE L'UTÉRUS DE RATS, ET AYANT DE PRÉFÉRENCE, IN VIVO, UNE ACTION PLUS MARQUÉE SUR LES OVAIRES QUE SUR L'UTÉRUS ; LEUR PRODUCTION ; LEUR UTILISATION AUX FINS THÉRAPEUTIQUES ET LEUR FORMES PHARMACEUTIQUES, DESTINÉES À ÊTRE ADMINISTRÉES, RENFERMANT CES NOUVEAUX COMPOSÉS.
MA32490A 2007-07-12 2010-01-07 Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs MA31565B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (fr) 2007-07-12 2007-07-12 Estratriènes 8 bêta substitués servant d'oestrogènes sélectivement actifs

Publications (1)

Publication Number Publication Date
MA31565B1 true MA31565B1 (fr) 2010-08-02

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32490A MA31565B1 (fr) 2007-07-12 2010-01-07 Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs

Country Status (34)

Country Link
US (1) US20090029957A1 (fr)
EP (2) EP2014672A1 (fr)
JP (1) JP2010533152A (fr)
KR (1) KR20100037593A (fr)
CN (1) CN101687902B (fr)
AR (1) AR067507A1 (fr)
AU (1) AU2008274198A1 (fr)
BR (1) BRPI0814207A2 (fr)
CA (1) CA2692727A1 (fr)
CL (1) CL2008002027A1 (fr)
CO (1) CO6270230A2 (fr)
CR (1) CR11211A (fr)
CU (1) CU23885B1 (fr)
CY (1) CY1113351T1 (fr)
DK (1) DK2176282T3 (fr)
DO (1) DOP2010000017A (fr)
EA (1) EA017124B1 (fr)
EC (1) ECSP109872A (fr)
ES (1) ES2393942T3 (fr)
HN (1) HN2010000081A (fr)
HR (1) HRP20120952T1 (fr)
MA (1) MA31565B1 (fr)
NZ (1) NZ582490A (fr)
PA (1) PA8789401A1 (fr)
PE (1) PE20090825A1 (fr)
PL (1) PL2176282T3 (fr)
PT (1) PT2176282E (fr)
RS (1) RS52541B (fr)
SI (1) SI2176282T1 (fr)
TN (1) TN2010000007A1 (fr)
TW (1) TW200911824A (fr)
UA (1) UA99918C2 (fr)
UY (1) UY31220A1 (fr)
WO (1) WO2009007454A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830984C (fr) * 2011-03-25 2020-02-11 Universite Laval Inhibiteurs de 17.beta.-hsd1, 17.beta.-hsd3 et 17.beta.-hsd10.
US10744439B2 (en) * 2016-06-24 2020-08-18 K&N Engineering, Inc. Compound air filter and method of removing airborne molecular contaminants and volatile organic compounds therefrom
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
AU2001258341B2 (en) * 2000-04-12 2007-03-15 Schering Aktiengesellschaft 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
EA201000097A1 (ru) 2010-08-30
PA8789401A1 (es) 2009-04-23
TW200911824A (en) 2009-03-16
SI2176282T1 (sl) 2013-02-28
CN101687902B (zh) 2013-07-24
WO2009007454A2 (fr) 2009-01-15
EA017124B1 (ru) 2012-10-30
EP2176282B1 (fr) 2012-08-22
HRP20120952T1 (hr) 2012-12-31
CA2692727A1 (fr) 2009-01-15
NZ582490A (en) 2012-03-30
WO2009007454A3 (fr) 2009-03-05
CO6270230A2 (es) 2011-04-20
DK2176282T3 (da) 2012-12-03
JP2010533152A (ja) 2010-10-21
RS52541B (en) 2013-04-30
AR067507A1 (es) 2009-10-14
DOP2010000017A (es) 2010-01-31
CL2008002027A1 (es) 2009-01-16
CU23885B1 (es) 2013-04-19
PE20090825A1 (es) 2009-07-25
ES2393942T3 (es) 2013-01-02
AU2008274198A1 (en) 2009-01-15
EP2014672A1 (fr) 2009-01-14
PL2176282T3 (pl) 2013-06-28
CR11211A (es) 2010-04-27
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
BRPI0814207A2 (pt) 2015-01-27
CY1113351T1 (el) 2016-06-22
UY31220A1 (es) 2009-03-02
PT2176282E (pt) 2012-11-30
ECSP109872A (es) 2010-02-26
HN2010000081A (es) 2013-07-01
EP2176282A2 (fr) 2010-04-21
CN101687902A (zh) 2010-03-31
US20090029957A1 (en) 2009-01-29
CU20100008A7 (es) 2011-05-27
UA99918C2 (ru) 2012-10-25

Similar Documents

Publication Publication Date Title
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA41111B1 (fr) Compositions anticancéreuses
MA20150065A1 (fr) Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA33220B1 (fr) Composition pharmaceutique a proprietes anti-inflammatoires
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
Krauwinkel et al. The effect of mirabegron, a potent and selective β 3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
MA33405B1 (fr) Anticorps anti-axl
MA31953B1 (fr) Nouveaux derives du thiophene.
WO2007027941A3 (fr) Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
MA38147A1 (fr) Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
CY1112106T1 (el) Σκευασματα παραθυρεοεiδους ορμονης και η χρηση τους
HN2008000360A (es) Dispersiones amorfas solidas
WO2007139815A3 (fr) Procédé d'imagerie et de thérapie utilisant des cellules progénitrices
CL2007001784A1 (es) Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado.
WO2011053901A3 (fr) Nanostructures magnetiques utilisees en tant qu'agents theranostiques
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
MA34981B1 (fr) Formulations comprenant 2-amino-2-2-4-octylphenyl)ethyl)propane-1,3-diol
MA31565B1 (fr) Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
CA2542780A1 (fr) Medicament et aliment/boisson pour le soulagement de l'hyperglycemie
CL2018000131A1 (es) Inmunoconjugados de il22